Agilent Technologies Inc vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.22B), while Rex Fang & Innovation Equity Premium Income ETF trades at $41.8. The key difference: Agilent Technologies Inc pays a 0.68% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| A | FEPI | |
|---|---|---|
Market Cap | $42.22B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $157.20 | $49.54 |
52-Week Low | $110.24 | $37.98 |
Enterprise Value | $43.77B | — |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.23, near its consensus price target of $154.90, with a slight 0.33% decline over 24 hours. The stock shows strong fundamentals, including a 19.55% net income margin and robust ROE of 21.33%, while technical indicators signal a bullish trend despite overbought RSI levels. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, reinforcing growth in biopharma services.
Outlook remains positive with 77.5% analyst buy ratings, but risks include high valuation multiples (P/E 30.02) and dependence on healthcare spending. Earnings beat in Q1 2026 supports upside, though Q2 2026 results due August 26 are critical for momentum. Institutional accumulation, like Ashton Thomas Securities' 47.1% stake increase in Q2 2026, underscores confidence.
FEPI trades at $41.80, showing slight daily weakness with a 0.17% decline. The ETF maintains a bullish technical signal with strong moving average support and weekly dividend distributions averaging $0.20-0.21. Recent news highlights FEPI's aggressive covered call strategy targeting AI and mega-cap tech names to generate its 25% yield, though analysts caution about NAV erosion risks during market downturns.
The outlook remains cautiously optimistic given the bullish technical setup and high income generation, but investors face significant risk from the concentrated tech portfolio and covered call strategy that limits upside potential. Market sentiment is divided between yield-seeking investors and those concerned about long-term NAV preservation in volatile market conditions.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →